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using the UKPDS risk engine. Statin adherence was measured as pill days cov-
ered (PDC) in the IADB.nl pharmacy research database. Cost-effectiveness was 
measured in costs per quality-adjusted life-year (QALY) form the health care-
payers’ perspective. Results: For an average patient aged 60 at diagnosis, statin 
treatment was highly cost-effective at around € 2,300 per QALY. Favourable cost-
effectiveness was robust in sensitivity analysis. Differences in age and 10-year 
cardiovascular risk showed large differences in cost-effectiveness from more 
than € 100,000 per QALY to almost being cost saving. For the average patient aged 
40 at diabetes diagnosis, statin treatment for primary prevention was not cost-effec-
tive. ConClusions: Despite the non-adherence levels observed in actual practice, 
statin treatment is cost-effective for primary prevention in patients newly diagnosed 
with type 2 diabetes. Due to large differences in cost-effectiveness according to differ-
ent risk and age groups, the efficiency of the treatment could be increased by targeting 
patients with relatively higher cardiovascular risk and higher ages.
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objeCtives: Patients with a recent transient ischemic attack (TIA) or minor ischemic 
stroke who receive medicines have a 10-year risk of about 16% for any recurrent 
stroke. Non-invasive molecular imaging technologies are currently being developed 
to improve individual stroke risk prediction. We estimated the potential lifetime cost-
effectiveness of a novel imaging test for stroke prediction in an early stage of develop-
ment. Methods: Decision modelling was used to estimate the potential value of an 
add-on test that could identify which patients with a recent TIA or minor ischemic 
stroke should undergo surgery instead of receive medicines. The comparator was 
patient management according to Dutch guidelines. Test sensitivity and specificity 
were varied from 0-100% and its cost was set at € 350. Different age- and gender-spe-
cific subgroups were examined to see how much cost-effectiveness varied. Results: 
A perfect add-on test (100% sensitivity and specificity) for 60-year-old men appears to 
be cost-effective versus Dutch guidelines, with an estimated 0.61 QALY gain, € 3,986 
cost increase, and an incremental cost-effectiveness ratio (ICER) of € 6,534/QALY 
gained. A test with sensitivity= 60% and specificity= 100% increases both health (0.14 
QALYs) and costs (€ 2,888), resulting in an ICER of € 20,338/QALY gained. Similarly, a 
test with sensitivity= 100% and specificity= 60% increases both health (0.29 QALYs) 
and costs (€ 5,784), resulting in an ICER of € 19,946/QALY gained. ConClusions: An 
imaging test that improves risk prediction and therefore treatment decisions for 
patients with a recent TIA or minor ischemic stroke has the potential to optimize cost-
effectiveness by reducing the risk of recurrent stroke. However, reduced sensitivity 
or specificity of the test reduces its cost-effectiveness versus the Dutch guidelines. 
Developers must consider if the minimum level of accuracy required to be cost-effec-
tive is close to the maximum capability of the test. Model-based analyses are valu-
able in facilitating decisions about investments in the further development of a test.
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objeCtives: At the population level, disease management programs (DMPs) for heart 
failure (HF) have proven to be effective in increasing quality-adjusted survival and 
reducing the rate of hospital readmission. However, a systematic assessment as to 
whether these outcomes could still be improved upon by tailoring the content and 
structure of such DMPs to the risk profile of the individual patient has not yet been 
conducted. Using data from a previously conducted randomized controlled trial, the 
purpose of this study was to explore the clinical and health economic consequences 
of assigning different DMPs to different risk categories of HF patient. Methods: The 
analysis was conducted alongside the COACH study, in which 1023 patients were ran-
domly assigned to one of three DMPs: care-as-usual (routine follow-up by a cardiolo-
gist), basic additional support by a nurse specialized in HF management (HF-nurse), 
and intensive additional support by an HF-nurse. The Subpopulation Treatment Effect 
Pattern Plot (STEPP) methodology was applied to graphically establish suitable cut-
offs for stratifying patients into different risk categories based on their predicted 
18-month mortality risk. Separate cost-effectiveness analyses were subsequently 
performed within each of these strata to determine per risk category the DMP that 
would be optimal in terms of survival time and costs. Results: Based on the STEPP 
analysis, a cut-off of 0.17 was selected to classify 346 (33.8%) patients as low risk and 
677 (66.2%) patients as high risk. At a threshold value of € 10,000 per life-year, this 
resulted in an 82.9% probability that intensive support would be optimal for low-risk 
patients and an 83.6% probability that basic support would be optimal for high-risk 
patients. ConClusions: Assigning different DMPs to different risk groups of patient 
improved outcomes and reduced costs. Tailoring the content and structure of such 
programs to the risk profile of the individual patient seems therefore desired.
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objeCtives: Dabigatran was recommended by the Pharmaceutical Benefits 
Advisory Committee (PBAC) in March 2011 for the treatment of non-valvular atrial 
fibrillation (NVAF) but was not listed on the Pharmaceutical Benefits Scheme (PBS) 
for over two years. This analysis examines the cost-effectiveness of dabigatran 
and the opportunity cost of delayed reimbursement from a societal perspec-
tive. Methods: This analysis estimated the costs for dabigatran compared with 
warfarin and a mixed comparator (warfarin/aspirin/untreated) reflective of current 
ICER of € 11,000/QALY which is below the threshold deemed acceptable from Italian 
payers (25.000€ -40.000€ ). In the subgroups analyses, rivaroxaban demonstrated to 
be a dominant strategy (more effective and less costly). Sensitivity analyses showed 
the robustness of the results. ConClusions: Rivaroxaban is a cost-effective alter-
native to VKA and is cost-saving for the SSN in the treatment of NVAF patients at 
highest unmet medical need.
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objeCtives: To estimate the cost-effectiveness of dabigatran etexilate (dabigatran) 
for the secondary prevention of deep vein thrombosis (DVT) and pulmonary embo-
lism (PE) from the perspective of the UK National Health Service. Methods: A 
Markov model was developed to estimate costs and outcomes over the lifetime of 
a cohort of patients receiving either dabigatran (150mg given orally, twice daily) 
or placebo for 6 months after having completed 6 to 18 months of anticoagulation 
treatment for a DVT or PE. Modelled events included recurrent DVT and PE, major 
bleeding (including long-term disability from intracranial haemorrhage), clinically 
relevant non-major bleeding, myocardial infarction, unstable angina, pulmonary 
hypertension, severe postthrombotic syndrome, and death. Efficacy and safety 
parameters were based on the RE-SONATE study; the period of follow-up was 6 
months with an extension to 18 months. Probabilities of recurrent DVT and PE after 
trial follow-up were based on a prospective cohort study of 1,626 patients followed-
up for a median of 50 months and were assumed to be equivalent in both treatment 
groups. Utility estimates were based on EQ-5D data collected in dabigatran trials and 
published literature. The mean duration of therapy was based on the RE-SONATE 
study; other costs were based on NHS Reference Costs and published literature. 
Costs and outcomes were discounted at 3.5% per annum. Univariate and probabilis-
tic sensitivity analyses were performed. Results: In the base-case analysis, mean 
total costs for dabigatran and placebo patients were £7,147 and £7,520 respectively; 
mean QALYs were 13.089 and 13.070 respectively. Dabigatran was dominant; the 
probability of cost-effectiveness at a willingness-to-pay threshold of £20,000 per 
QALY was 63%. In univariate sensitivity analysis, dabigatran was dominant in all 
analyses. ConClusions: This analysis suggests that dabigatran is likely to be cost-
saving compared to placebo for the secondary prevention of DVT and PE in the UK.
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objeCtives: Statins are the standard treatment for cardiovascular disease (CVD) 
prevention however, with limited effect on triglyceride (TG) and high-density lipo-
protein-cholesterol (HDL-C) in mixed hyperlipidemia. Fenofibric acid (FA) is approved 
for co-administration with statins to reduce TG and increase HDL-C in patients with 
mixed hyperlipidemia at goal for LDL-C with statins. This study assesses the cost-
effectiveness of FA combined with low (LDS) or medium (MDS) dose statins versus 
low, medium or high (HDS) dose statins alone in the prevention of CVD in Taiwanese 
patients with type 2 diabetes and mixed hyperlipidemia. Methods: A 5-health-
state Markov model for diabetic patients with mixed hyperlipidemia already 
treated with statin (TG:250mg/dl; HDL-C:35mg/dl; LDL-C:115mg/dl; TC:200mg/dl) 
was developed, using a lifetime horizon with annual cycles. PROCAM (first event) 
and Framingham (subsequent event) risk equations were used. Effects on TG, HDL-C 
and TC for each comparator were derived from pooled simvastatin, atrovastatin 
and rosuvastatin trials. Drug and event costs were based on official national data-
bases. Annual discounting (5%) was applied to outcomes and costs. Incremental cost 
(€ ) per Quality of Life Gained (QALYG) was calculated from the Taiwanese Bureau 
of National Health Insurance perspective. Results: Compared to LDS and MDS, 
treatment with FA+LDS resulted in higher costs (€ 2,225; € 1,676) but more QALYG 
(0.311; 0.064), resulting in an incremental cost-effectiveness ratio of € 7,161/QALYG 
and € 26,375/QALYG respectively. Compared to HDS, FA+LDS costs were lower with 
slightly less QALYG (ICER: € 183,490/QALYG). Compared to FA+MDS, FA+LDS was 
dominant with lower costs (-€ 900) and higher QALYG (0.004). Sensitivity analyses 
showed robustness of the results. The probability for FA+LDS being cost-effective 
(< GDP threshold € 45,400) is 100% for both, LDS and MDS. ConClusions: In this 
specific mixed hyperlipidemia population, FA+LDS is likely to be a cost-effective 
alternative to LDS or MDS alone, potentially allowing for lower statin doses in pre-
venting CVD.
PCV83
Cost-effeCtIVeness of statIns for PrImary PreVentIon In neWly 
DIagnoseD tyPe 2 DIabetes PatIents In the netherlanDs
de Vries F.M.1, Denig P.2, Visser S.T.1, Hak E.1, Postma M.J.1
1University of Groningen, Groningen, The Netherlands, 2University Groningen, Groningen, The 
Netherlands
objeCtives: Statins reduce the risk of cardiovascular events in patients 
with diabetes. The aim of this study is to determine whether statin treatment 
for primary prevention in newly diagnosed type 2 diabetes is cost-effective, 
taking non-adherence, baseline risk, and age into account. Methods: A cost-
effectiveness analysis was performed using a Markov model with a time horizon 
of 10 years. The baseline 10-year cardiovascular risk was estimated in a Dutch 
population of primary prevention patients with newly diagnosed diabetes from 
the Groningen Initiative to Analyse Type 2 Diabetes Treatment database (GIANTT), 
